Unknown

Dataset Information

Inhibition of iRhom1 by CD44-targeting nanocarrier for improved cancer immunochemotherapy.


ABSTRACT: The multifaceted chemo-immune resistance is the principal barrier to achieving cure in cancer patients. Identifying a target that is critically involved in chemo-immune-resistance represents an attractive strategy to improve cancer treatment. iRhom1 plays a role in cancer cell proliferation and its expression is negatively correlated with immune cell infiltration. Here we show that iRhom1 decreases chemotherapy sensitivity by regulating the MAPK14-HSP27 axis. In addition, iRhom1 inhibits the cytotoxic T-cell response by reducing the stability of ERAP1 protein and the ERAP1-mediated antigen processing and presentation. To facilitate the therapeutic translation of these findings, we develop a biodegradable nanocarrier that is effective in codelivery of iRhom pre-siRNA (pre-siiRhom) and chemo

SUBMITTER: Luo Z 

PROVIDER: S-EPMC10766965 | biostudies-literature | 2024 Jan

REPOSITORIES: biostudies-literature